English
Home > Products > Favipiravir advance intermediate

China Favipiravir advance intermediate Factory

We have now probably the most innovative production equipment, experienced and qualified engineers and workers, regarded high quality control systems and also a friendly expert income team pre/after-sales support for Favipiravir advance intermediate,CAS NO 259793-88-9,259793-88-9,Favipiravir intermediate,6-bromo-3-hydroxypyrazine-2-carboxamide, For even more inquires make sure you will not wait to make contact with us. Thank you - Your help continuously inspires us.
Favipiravir advance intermediate, Now, we are trying to enter new markets where we do not have a presence and developing the markets we have now the already penetrated. On account of superior quality and competitive price , we'll be the market leader, please don??￥t hesitate to contact us by phone or email, if you are interested in any of our goods.

Related Products

Hot Products

  • Linezolid

    Linezolid

    Product Name:Linezolid
    Molecular Formula:C16H20FN3O4
    Molecular Weight:337.35
    CAS Registry Number:165800-03
  • 1,2-Diaminocyclohexane

    1,2-Diaminocyclohexane

    Product Name:1,2-Diaminocyclohexane
    Molecular Formula:C6H14N2
    Molecular Weight:114.19
    CAS Registry Number:694-83-7
  • Borane tert-butylamine complex

    Borane tert-butylamine complex

    Product Name:Borane tert-butylamine complex
    Molecular Formula:C4H11BN
    Molecular Weight:83.94784
    CAS Registry Number:7337-45-3
  • (R)-(+)-a,a-Diphenyl-2-pyrrolidinemethanol

    (R)-(+)-a,a-Diphenyl-2-pyrrolidinemethanol

    Product Name:(R)-(+)-a,a-Diphenyl-2-pyrrolidinemethanol
    Molecular Formula:C17H19NO
    Molecular Weight:253.35
    CAS Registry Number:22348-32-9
  • Diacerein

    Diacerein

    Product Name:Diacerein
    Molecular Formula:C19H12O8
    Molecular Weight;368.29
    CAS Registry Number;13739-02-1
  • Fluorocytosine

    Fluorocytosine

    Product Name:Fluorocytosine
    Molecular Formula:C4H4FN3O
    Molecular Weight:129.09
    CAS Registry Number:2022-85-7
  • Related Blog
  • Reviews

  • What are pharmaceutical intermediates?

    Pharmaceutical intermediates are fine chemical products in the production process from pharmaceutical chemical raw materials to bulk drugs or drugs. The synthesis of chemical drugs depends on high-quality pharmaceutical intermediates. This chemical, which does not require a drug production license, can be produced in ordinary chemical plants and can be used in the synthesis of drugs as long as it reaches certain grades.

  • Gilteritinib Fumarate

    Sandoo Pharmaceutica is a professional pharmaceutical intermediates manufacturer. We provide good quality Gilteritinib Fumarate Cas: 1254053-43-4. Welcome and we look forward to your inquiry!

  • Differences Between Pharmaceutical Raw Materials, Excipients and Pharmaceutical Intermediates

    In the pharmaceutical industry, there are various names of raw materials, such as pharmaceutical raw materials, pharmaceutical intermediates and pharmaceutical excipients in the process of pharmaceutical production. This article will take everyone to recognize these three concepts.

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications. Our products are produced under strict procedures and cGMP (Current Good Manufacturing Practices). In addtion, we can also customize new pharmaceutical compounds for new drugs.

  • How is a drug produced?

    ​There are so many different drugs ,with different color /shape ( like capsule ,tablet or Infusion) and price . Here we would like to explain , what makes it so different? How is a drug produced?

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept